A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Agatolimod; Incomplete Freund's adjuvant; Montanide ISA-51
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 May 2014 Biomarkers information updated
- 23 Jun 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 26 Nov 2008 Status changed from active, no longer recruiting to completed.